According to reports from Business Standard, Mankind Pharma delivered strong financial results for the quarter ended December 2025. The pharmaceutical company's consolidated net profit increased by 7.50% to ₹408.75 crore compared to ₹380.23 crore in the corresponding quarter of the previous year. This growth demonstrates the company's ability to maintain profitability while expanding operations.
As reported by Business Standard, the company's sales revenue rose 11.52% to ₹3,567.20 crore in Q3 FY2026, up from ₹3,198.79 crore in the same period last year. This significant revenue growth indicates strong market demand and effective business expansion strategies implemented by the company.
According to the financial data reported by Business Standard, the company's Operating Profit Margin (OPM) stood at 25.77% in Q3 FY2026, compared to 25.51% in the corresponding quarter of the previous year. Additionally, PBDT increased by 24% to ₹838.19 crore and PBT grew by 26% to ₹615.59 crore during the quarter.
As of December 31, 2025, Mankind Pharma shares were trading at ₹2,039.50, representing a 1.74% decline from the previous day's close of ₹2,062.9. The company has a market capitalization of ₹84,191.59 crore and 41.28 crore shares outstanding. The promoter group holds 72.66% stake in the company, while foreign institutional investors hold 11.34% and domestic institutional investors hold 13.22% as of December 2025.
According to market data, Mankind Pharma shares have shown mixed performance with a 52-week high of ₹2,716.50 and 52-week low of ₹2,031.00. The stock has delivered 13.75% returns over the last 12 months and 0.0% returns over the last 3 years. Analysts have set a median target price of ₹2,518.76 for the next 12 months with a high estimate of ₹3,100.00 and low estimate of ₹1,990.00.
